FALLING out of bed, I set the Nespresso machine to do what it does best and brew up my morning wake-me-up. Sliding open the ...

Save on rent, live by the Mediterranean, and do good at the same time: On the Greek island of Syros, volunteers can live for ...

Hundreds of below-market price homes are on the way across Cyprus, with construction already under way on part of the ...

Shares in Agios Pharma lost nearly half their value in pre-market trading today after it posted mixed clinical results from a phase 3 trial of its sickle cell disease (SCD) therapy mitapivat, sending ...

As overtourism and extreme heat take over several of Europe’s most popular southern destinations, more destination dupes are ...

A detailed breakdown of how toll prices are being adjusted across the country’s motorways following the increases that came ...

A detailed breakdown of how toll charges will be shaped on the country’s motorways following the increases from 1 January ...

Nestled below the blue dome of Agios Nikolaos Church, where colourful boats bob and curious pelicans drift by, Kadena serves Mykonos on a plate.

From Mykonos, a one-hour crossing takes you to Syros – the Cyclades' neoclassical capital and a hidden maritime treasure.

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients ...

Agios Pharmaceuticals, Inc. stock plunged 49% after mixed Phase 3 results for mitapivat in Sickle Cell Disease, raising doubts about future approvals. Mitapivat met the primary hemoglobin endpoint but ...

In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle ...